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ABSTRAK
Latar belakang: diabetes melitus (DM) meningkatkan risiko terjadinya TB aktif sebesar tiga kali; saat ini 
belum ada strategi pengobatan yang spesifik untuk pasien tuberkulosis-DM (TB-DM). Panduan WHO 2017 tidak 
lagi merekomendasikan pemberian obat secara intermiten pada pengobatan TB fase lanjutan karena tingginya 
risiko kegagalan, relaps, dan resistensi obat dibandingkan dengan pemberian setiap hari. Penelitian ini bertujuan 
untuk membandingkan efektivitas pengobatan fase lanjutan dengan kedua cara pemberian tersebut, dalam hal 
respons klinik dan konversi sputum, pada pasien TB-DM. Metode: studi kohort retrospektif menggunakan rekam 
medik pasien rawat jalan Rumah Sakit Pesahabatan, Jakarta mulai 1 januari 2015 hingga 31 desember 2018. 
Kriteria inklusi adalah semua pasien TB-DM berusia >18 tahun tanpa HIV dengan pemeriksaan sputum positif 
pada saat diagnosis, yang mendapat pengobatan kategori 1 dan telah memasuki fase lanjutan. Hasil: sebanyak 
72 pasien memenuhi kriteri inklusi (75% laki-laki and 88.8% setidaknya memiliki hasil pemeriksaan sputum 1+ 
pada saat diagnosis). Tiga puluh subyek belum mengalami konversi pada awal pengobatan fase lanjutan. Pada 
akhir fase lanjutan, 44.2% pada kelompok intermiten dan 41.4% pada kelompok pengobatan setiap hari dinyatakan 
sembuh. Tujuh subyek mengalami efek samping; tetapi terdapat banyak pasien putus obat dan tidak dapat dijelaskan 
penyebab putus obat terkait dengan efek samping atau tidak. Kesimpulan: tidak didapatkan perbedaan dalam 
profil konversi sputum dan keberhasilan pengobatan TB kategori 1-DM fase lanjutan antara pemberian intermiten 
dan setiap hari pada pasien diabetes.
Kata kunci: TB-DM, diabetes melitus, fase lanjutan, pengobatan intermiten, pengobatan setiap hari, 
keberhasilan pengobatan.
ABSTRACT
Background: diabetes mellitus (DM) increases the risk of active TB by three times; there is no specific 
treatment strategy for tuberculosis-DM (TB-DM) patients. The 2017 WHO guidelines no longer recommended 
an intermittent regimen in the advanced phase of TB treatment due to higher risk of failure, relapse, and drug 
resistance compared to the daily regimen. This study aims to compare the effectiveness of treatment, in terms of 
clinical response and sputum conversion, of TB-DM patients in the advanced phase between the two-treatment 
delivery schedules. Methods: a retrospective cohort study from the medical records of patients from 1 January 
2015 to 31 December 2018 at Persahabatan Hospital, Jakarta. The inclusion criteria are TB-DM patients aged 
>18 years with non-reactive HIV test, who have entered the advanced phase of category 1 TB treatment with smear 
positive at the time of diagnosis. Results: a total of 72 patients met the inclusion criteria. (75% male and 88.8% 
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INTRODUCTION
Tuberculosis (TB) is the largest cause of 
morbidity and mortality among infectious 
diseases in the world.1 In 2017, 10 million people 
worldwide suffered from TB and 1.7 million 
people are estimated to have latent TB infection 
and at risk of developing active TB disease 
during their lifetime. Indonesia has the third 
highest number of TB cases in the world.2 Early 
diagnosis and adequate therapy of TB patients 
are the primary treatment strategies.3
Diabetes mellitus (DM) increases the risk 
of active TB by three times,4 and pulmonary TB 
is the 9th most frequent complication in DM.5 
The prevalence of TB-DM in Southeast Asia 
is 14% and 14.8% in Indonesia.6 A systematic 
review revealed that TB prevalence in DM 
patients is around 1.7–36% and DM prevalence 
in TB patients is around 1.9–35%.7 Patients 
with HbA1c ≥7% have 2.5 times greater risk of 
developing TB compared to those with HbA1c 
≤7%.8 Good glycemic control can reduce the risk 
of developing TB in DM patients.9 The risk of 
death, treatment failure, and relapse is very high 
in TB-DM patients.10,11 The risk of death is around 
6.5–6.7 times higher in TB-DM patients.12 Blood 
glucose management of DM patients in chronic 
inflammatory state is extremely difficult, while 
TB is a chronic inflammatory disease.13 Recent 
research found that TB worsens glycemic control 
in DM patients, and failure of TB treatment in 
DM patients increases by 69% and risk of relapse 
four times.14
An optimal treatment strategy for TB-DM 
patients has not been found, and there is no 
scientific evidence supporting the difference 
in regimens between TB only and TB-DM 
patients.13 Based on 2011 WHO guidelines, 
TB-DM management is the same as non-DM. 
In the intensive phase, four antituberculosis 
drugs (rifampicin, isoniazid, pyrazinamide, and 
ethambutol) are given daily for two months, 
followed by an advanced phase, in which two 
antituberculosis drugs (rifampicin and isoniazid) 
are given daily or intermittently three times a 
week for four months when blood sugar is well 
controlled, or it will be extended to seven months 
when blood sugar is poorly controlled.15
In 2017, World Health Organization (WHO) 
no longer recommended intermittent treatment 
in advanced phase. This was supported by a 
systematic review of intermittent therapeutic 
regimens in 2009; randomized control trials show 
that intermittent treatment has a higher risk of 
failure, relapse, and drug resistance compared 
to daily treatment.16
TB is  diagnosed based on sputum 
examination,3 which is also used for assessing 
treatment success. Sputum examination is 
usually performed at the end of the 2nd, 4th, 
and 5th month. The treatment of TB patient 
is considered unsuccessful if the sputum 
conversion is not achieved by the end of the 
fifth month of therapy.17 No study in Indonesia 
has been conducted to compare the outcome of 
advanced phase treatment in TB-DM patients 
between intermittent and daily regimens. This 
study aims to compare the effectiveness of 
treatment in terms of clinical response and 
sputum conversion of TB-DM patients in the 
advanced phase between the two-treatment 
delivery schedules.
METHODS
This cohort retrospective study was conducted 
at Persahabatan Hospital, Jakarta. Data was taken 
had at least 1+ smear results at the time of diagnosis). Thirty subjects still have positive smear at the beginning of 
the advance phase of treatment. After the advanced phase, 44.2% in the intermittent and 41.4% in the daily group 
were cured or having sputum conversion. Seven subjects had side effects; but there were lots of dropouts and it is 
unclear whether they dropped because of side effects or not. Conclusion: there is no difference between sputum 
conversion profile and treatment success in advanced phase TB-DM treatment category 1 between the daily and 
intermittent regimen.ly for diabetic patients.
Keywords: TB-DM, diabetes mellitus, advanced phase, intermittent treatment, daily treatment, treatment 
success.
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from all the medical records of TB-DM patients 
receiving category 1 TB treatment in the period 
of 1 January 2015 to 31 December 2018. The 
study secured ethical approval from the research 
ethics committee of Persahabatan Hospital. The 
inclusion criteria were TB-DM patients aged 
>18 years who had entered the advanced phase 
of TB treatment category 1 (2RHZE/4RH or 
2RHZE/4R3H3) with smear positive at the 
beginning of TB treatment and non-reactive HIV 
test. The cohort were followed from the start of 
the adavanced phase up to the end of the treatment 
period. Data collected from the patients medical 
records, were analyzed comparing patients that 
had received the intermittent regimen using fixed 
dose combination (FDC) of three times a week 
and the ones that had received daily regimen 
using individual tablets. The dosage given was 
in accordance with the Indonesian guideline. 
This study observed the documented end results 
of treatment at the end of each patients advance 
phase. Statistical tests were performed using SPSS 
20.0 and the method used to compare the results 
of treatment of the two groups (proportion of 
success) was X2 test.
This study has been approved by the Ethical 
Committee of Persahabatan Hospital (Reference 
number 25/KEPK-RSUPP/04/2019).
RESULTS
From 704 medical records of patient who 
registered as TB-DM patients from January 1, 
2015 until December 31, 2018, 134 patients 
had entered the advanced phase of TB treatment 
category 1. From those 134 patients, only 72 
patients met the inclusion criteria. Table 1 
presents the basic characteristics of these 72 
patients. Fifty-four subjects (75%) were male, 
68.1% were in the age group 46–65 , 76.4% had 
body weight 40–60 kg, and 64 patients had at 
least 1+ smear results (88.9%). Thirty patients 
(41.7%) did not reach conversion at the end of the 
intensive phase of treatment (Table 2). For seven 
Table 1. Basic characteristics (N = 72)
Intermittently thrice a week (N = 43)
n (%)





 - Male 31 (72.1) 23 (79.3) 54 (75.0)
 - Female 12 (27.9) 6 (20.7) 18 (25.0)
Age group
 - 18–25 years 0 1 (3.4) 1 (1.4)
 - 26–45 years 9 (20.9) 9 (31.0) 18 (25.0)
 - 46–65 years 30 (69.8) 19 (65.5) 49 (68.1)
 - >65 years 4 (9.3) 0 4 (5.6)
Body weight
 - <40 kg 1 (2.3) 1 (3.4) 2 (2.8)
 - 40–60 kg 31 (72.1) 24 (82.8) 55 (76.4)
 - >60 kg 11 (25.6) 4 (13.8) 15 (20.8)
Smear
 - 1–9 bar 5 (11.6) 3 (10.3) 8 (11.1)
 - 1 positive 13 (30.2) 11 (37.9) 24 (33.3)
 - 2 positive 12 (28.0) 6 (20.7) 18 (25.0)
 - 3 positive 13 (30.2) 9 (31.0) 22 (30.6)
Table 2. Sputum conversion at the beginning of advance phase (N = 72)
Sputum conversion Intermittently thrice  a week (N = 43) - n (%)
Daily (N = 29)
n (%)
Total
n (%) P value
Conversion 26 (60.5) 16 (55.2) 42 (58.3) 0.276
No conversion 17 (39.5) 13 (44.8) 30 (41.7)
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patients, conversion happened at the end of the 
3rd month, and 12 patients dropped out before 
conversion. After the advanced phase, thirty-
one subjects were cured (Table 3), 19 (44.2%) 
in the intermittent group and 12 (41.4%) in the 
daily group. Lost to follow up were similar for 
both groups (46.5% vs. 51.7%). Seven subjects 
had side effects (Table 4), 6 in the intermittent 
(14%) and 1 in the daily treatment (4%); but there 
were a lot of dropouts without information and 
it remained unclear whether they dropped out 
because of side effects or not.
DISCUSSION
In this study, the number of male subjects 
in both groups was greater than female subjects 
(75% vs 25%). This result is consistent with 
WHO’s 2018 global report data which states that 
in 2017, the majority of TB patients were male,2 
and the 2017 International Diabetes Federation, 
which reported that DM mostly occurs in males.18 
The largest number of subjects were aged 46–65 
years (68.1%) with body weight between 40–60 
kg (76.4%), sputum examination results at least 
1+ (88.8%), and 30 patients (41.7%) remain 
positive at the end of the intensive phase. The 
results is consistent with Riza et al.13 who found 
that patients with TB-DM were mostly elderly, 
with a higher body mass index, and positive 
examination results, which usually remained 
positive at the end of the 2nd month of the 
intensive phase treatment.13 Conversely, Har 
Ashish Jinda et al.19 found that 32.7% remained 
positive at the end of the 4th week.
Success rate, failure, and dropouts were 
comparable in both groups. This differs from 
WHO’s statement that the intermittent thrice 
a week regimen entails a higher risk of failure 
compared to the daily regimen.16 Success rate in 
the intermittent group was only 44.2%, which 
differs from the treatment success observed in 
Mexico, 71.35%;11 and treatment success in 
the daily group was only 41.4%, which differs 
from Cameroon’s 90%.20 Failure of treatment 
occurred in three patients, one in the intermittent 
group and two in the daily group. One in the 
daily group failed due to reversion at the end 
of the 5th month, and the others failed due to 
delayed sputum conversion until the end of 5th 
month of treatment, and their sputum culture 
results showed monoresistance to INH. This is in 
contrast to Argita et al.’s21 study: TB patients with 
isoniazid monoresistance have the same response 
to sputum conversion and treatment results as 
patients who are sensitive to all tuberculosis 
drugs. These results were in accordance  with the 
Ministry of Health of the Republic of Indonesia’s 
report: the results of TB treatment in DM patients 
had a greater number of failures due to delayed 
sputum conversion.22 Thirty- eight subjects were 
dropouts, 12 of them dropouts since they entered 
Table 4. Adverse effect (N = 72)
Adverse
effect
Intermittently thrice  
a week (N = 43) - n (%)
Daily (N = 29)
n (%)
Total
n (%) P value
No 37 (86.0) 28 (96.6) 65 (90.3) 0.219
Itching 1 (2.3) 0 1 (1.4)
Tingling 3 (7) 0 3 (4.2)
Joint paint 2 (4.7) 0 2 (2.8)
Nausea 0 1 (3.4) 1 (1.4)
Table 3. Treatment result (N = 72)
Treatment result Intermittently thrice  a week (N = 43) - n (%)
Daily (N = 29)
n (%)
Total
n (%) P value
Cure 19 (44.2) 12 (41.4) 31 (43.1) 0.634
Lost to follow up 23 (53.5) 15 (51.7) 38 (51.7)
Failed 1 (2.3) 2 (6.9) 3 (4.2)
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the advanced phase and their follow up could not 
be performed. These results were similar with 
Mi Feng Ling et al.’s, that TB-DM patients have 
higher dropouts rate.23
Seven patients experienced side effects, 
mostly in the intermittent group (six vs. one). 
This result is different from Pranab Kumar 
Mandal et al.’s which reported more side effects 
in the daily treatment group.24
Strengths and Limitations of the Study
The strength of this study is that this is the first 
study comparing real world data of Indonesian 
TB-DM patients, assessing effectiveness and side 
effects of category 1 TB treatment at advanced 
phase between intermittent, thrice a week, and 
daily regimens. The data in this study was taken 
from the patients’ medical record, and the large 
number of lost to follow up patients make it 
impossible to get the picture of these patients 
response. There were not enough patients to 
meet the number of samples needed in this study, 
eventhough we have included all eligible TB-DM 
patients, with the consequence of lower power 
of the study.
CONCLUSION
Treatment effectiveness in terms of clinical 
response and sputum conversion between 
intermittent group (three times a week), and 
daily treatment group during advanced phase in 
TB-DM patients were comparable.
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